Skip to main content

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

Patients with advanced non–small cell lung cancer (NSCLC) whose tumors harbor anaplastic lymphoma kinase (ALK) gene fusions benefit from treatment with ALK inhibitors (ALKi). Analysis of cell-free circulating tumor DNA (cfDNA) may provide a noninvasive way to identify ALKfusions and actionable resistance mechanisms without an invasive biopsy.

View Abstract

Related Authors

Benjamin Philip Levy, M.D.

Benjamin Philip Levy, MD

Clinical Director of Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital

View full profile

Connect with Sibley Hospital

Connect with Surburban Hospital

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.